Recombinant Mouse ANGPTL3 Protein (His Tag)

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Catalog Number: PKSM041360



Description Species Mouse Mol Mass 22.7 kDa Accession O9R182 **Bio-activity** Not validated for activity **Properties** > 95 % as determined by reducing SDS-PAGE. Purity < 1.0 EU per µg of the protein as determined by the LAL method. Endotoxin Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 Storage °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at $< -20^{\circ}$ C for 3 months. This product is provided as lyophilized powder which is shipped with ice packs. Shipping Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4. Formulation Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. Please refer to the printed manual for detailed information. Reconstitution

Data

kDa	МК	R
120 90		
60	-	
40		
30		U
20	-	
14	-	

Background

Angiopoietin-likeProtein 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins. Mature mouse ANGPTL3 contains an N-terminalcoiled coil domain and a C-terminalfibrinogen-likedomain. Within the Nterminalfragment, mouse ANGPTL3 shares 83% and 92% aa sequence identity with human and rat ANGPTL3, respectively. ANGPTL3 is expressed in the liver from early in development through adulthood. ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymesresponsible for hydrolyzing circulating triglycerides and HDL phospholipids. This activity requires a putative heparin-bindingmotif which is N-terminalto thecoiled coil domain. Proteolytic removal of the fibrinogen-likedomain from the N-terminalfragment serves to activate ANGPTL3 and increase its ability toinhibit LPL in vitro and function in vivo. ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion oruptake. ANGPTL3 expression in vivo is up-regulated by LXR agonists anddown-regulated by insulin, leptin, and agonists of TRβ or PPARβ. ANGPTL3, secreted by fetal liver cells, also promotes the expansion of hematopoietic stem cells.

For Research Use Only